AstraZeneca holds talks with Bristol Myers Squibb on $512 billion megadeal: Report
The deal could create one of the world’s biggest pharmaceutical groups with a combined value of nearly US$400 billion, FT said.
- Center1
- Public / State1
no rewrites detected — all voices distinct
Summary
LONDON - UK drugmaker AstraZeneca has been exploring a deal to combine with US rival Bristol Myers Squibb, the Financial Times reported on Aug 2, citing people familiar with the matter. AstraZeneca declined to comment, while Bristol Myers did not immediately respond to a Reuters request for comment outside regular business hours.
Cross-referenced from 2 sources.
Factual coreconfirmed by several independent voices
Insufficient core: not enough independent confirmations to retain a shared fact.
Reported detailssecondary facts, each attributed to its source
LONDON - UK drugmaker AstraZeneca has been exploring a deal to combine with US rival Bristol Myers Squibb, the Financial Times reported on Aug 2, citing people familiar with the matter.
according to The Straits Times - WorldAstraZeneca declined to comment, while Bristol Myers did not immediately respond to a Reuters request for comment outside regular business hours.
according to The Straits Times - World
Disputedincompatible versions — to verify
No factual contradiction detected between sources.
Framing by sidesame fact, different words — loaded terms highlighted
No notable framing divergence.
Blind spotwhat one side keeps silent
No blind spot detected: every side covers the same facts.
Sources2 sources cross-checked
Center1
Public / State1